OBJECTIVE: While CVD risk has decreased in the general population during the last decade, the situation in patients with schizophrenia (SCZ) and bipolar disorder (BD) is unknown. METHODS: We compared CVD risk factors in patients with SCZ and BD recruited from 2002-2005 (2005 sample, N = 270) with patients recruited from 2006-2017 (2017 sample, N = 1011) from the same catchment area in Norway. The 2017 sample was also compared with healthy controls (N = 922) and the general population (N range = 1285-4587, Statistics Norway) from the same area and period. RESULTS: Patients with SCZ and BD in the 2017 sample had significantly higher level of most CVD risk factors compared to healthy controls and the general population. There was no significant difference in the prevalence of CVD risk factors in SCZ between the 2005 and 2017 samples except a small increase in glucose in the 2017 sample. There were small-to-moderate reductions in hypertension, obesity, total cholesterol, low-density lipoprotein, systolic and diastolic blood pressure in the BD 2017 sample compared to the 2005 sample. CONCLUSION: Despite major advances in health promotion during the past decade, there has been no reduction in the level of CVD risk factors in patients with SCZ and modest improvement in BD.
OBJECTIVE: While CVD risk has decreased in the general population during the last decade, the situation in patients with schizophrenia (SCZ) and bipolar disorder (BD) is unknown. METHODS: We compared CVD risk factors in patients with SCZ and BD recruited from 2002-2005 (2005 sample, N = 270) with patients recruited from 2006-2017 (2017 sample, N = 1011) from the same catchment area in Norway. The 2017 sample was also compared with healthy controls (N = 922) and the general population (N range = 1285-4587, Statistics Norway) from the same area and period. RESULTS:Patients with SCZ and BD in the 2017 sample had significantly higher level of most CVD risk factors compared to healthy controls and the general population. There was no significant difference in the prevalence of CVD risk factors in SCZ between the 2005 and 2017 samples except a small increase in glucose in the 2017 sample. There were small-to-moderate reductions in hypertension, obesity, total cholesterol, low-density lipoprotein, systolic and diastolic blood pressure in the BD 2017 sample compared to the 2005 sample. CONCLUSION: Despite major advances in health promotion during the past decade, there has been no reduction in the level of CVD risk factors in patients with SCZ and modest improvement in BD.
Authors: Shahram Bahrami; Nils Eiel Steen; Alexey Shadrin; Kevin O'Connell; Oleksandr Frei; Francesco Bettella; Katrine V Wirgenes; Florian Krull; Chun C Fan; Anders M Dale; Olav B Smeland; Srdjan Djurovic; Ole A Andreassen Journal: JAMA Psychiatry Date: 2020-05-01 Impact factor: 21.596
Authors: I H Heiberg; R Nesvåg; L Balteskard; J G Bramness; C M Hultman; Ø Naess; T Reichborn-Kjennerud; E Ystrom; B K Jacobsen; A Høye Journal: Acta Psychiatr Scand Date: 2020-02-29 Impact factor: 6.392
Authors: Victor Mazereel; Johan Detraux; Davy Vancampfort; Ruud van Winkel; Marc De Hert Journal: Front Endocrinol (Lausanne) Date: 2020-10-09 Impact factor: 5.555
Authors: Dani Beck; Ann-Marie G de Lange; Mads L Pedersen; Dag Alnaes; Ivan I Maximov; Irene Voldsbekk; Geneviève Richard; Anne-Marthe Sanders; Kristine M Ulrichsen; Erlend S Dørum; Knut K Kolskår; Einar A Høgestøl; Nils Eiel Steen; Srdjan Djurovic; Ole A Andreassen; Jan E Nordvik; Tobias Kaufmann; Lars T Westlye Journal: Hum Brain Mapp Date: 2021-10-09 Impact factor: 5.038
Authors: Eva Z Reininghaus; Mirko Manchia; Nina Dalkner; Nina Bonkat; Alessio Squassina; Isabel Hodl; Eduard Vieta; Andreas Reif; Tomas Hajek; Mikael Landén; Christoph U Correll; Jan Scott; Bruno Etain; Marcella Rietschel; Veerle Bergink; Monica Martinez-Cengotitabengoa; Lars Vedel Kessing; Andrea Fagiolini; Michael Bauer; Guy Goodwin; Ana Gonzalez-Pinto; Ralph W Kupka; Thomas G Schulze; Trine V Lagerberg; Ayşegül Yildiz; Chantal Henry; Gunnar Morken; Phillip Ritter; René Ernst Nieslen; Rasmus W Licht; Andreas Bechdolf; Ole A Andreassen; Frederike Tabea Fellendorf Journal: Eur Neuropsychopharmacol Date: 2021-09-10 Impact factor: 4.600